Osteopontin expression in plasma of melanoma patients and in melanocytic tumours

Maier, T., Laubender, R. P., Sturm, R. A., Klingenstein, A., Korting, H. C., Ruzicka, T. and Berking, C. (2012) Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. Journal of the European Academy of Dermatology and Venereology, 26 9: 1084-1091. doi:10.1111/j.1468-3083.2011.04210.x

Author Maier, T.
Laubender, R. P.
Sturm, R. A.
Klingenstein, A.
Korting, H. C.
Ruzicka, T.
Berking, C.
Title Osteopontin expression in plasma of melanoma patients and in melanocytic tumours
Journal name Journal of the European Academy of Dermatology and Venereology   Check publisher's open access policy
ISSN 0926-9959
Publication date 2012-09
Year available 2011
Sub-type Article (original research)
DOI 10.1111/j.1468-3083.2011.04210.x
Volume 26
Issue 9
Start page 1084
End page 1091
Total pages 8
Place of publication Oxford, U.K.
Publisher Wiley-Blackwell Publishing
Collection year 2013
Language eng
Formatted abstract
Background  While the serological tumour marker S100 is well established for the detection of metastatic melanoma, the extracellular matrix protein osteopontin (OPN) seems to be a promising novel marker for invasive melanoma.

Objectives  We analysed the potential of OPN as a serological tumour marker for metastatic melanoma and evaluated its combination with S100 and lactate dehydrogenase (LDH) levels to increase the reliability of these biomarkers for the detection of metastatic disease.

Methods  We examined OPN in the peripheral blood of 110 melanoma patients using enzyme-linked immunosorbent assay and combined it with S100 and LDH levels. In addition, the protein expression of OPN was analysed in tissue sections of melanocytic nevi and melanomas of different progression stages by immunohistochemistry.

Results  The independent comparison of S100 and OPN levels in metastatic vs. non-metastatic patients revealed a P-value <0.001 respectively. The predictiveness of OPN, S100 and LDH was 0.85, 0.89 and 0.69 as measured by the area under the receiver operating curve (AUC) respectively, while the combination of the two biomarkers OPN and S100 showed an AUC of 0.97. The optimal cut-off of the combination of OPN and S100 yielded a specificity of 85.9% and a sensitivity of 95.5%.

By immunohistochemistry, OPN protein expression was detected in 29% (7/24) of melanocytic nevi, 67% (30/45) of primary melanomas and 39% (7/18) of metastatic melanomas.

Conclusions  Together, OPN seems to be a promising novel biomarker for the detection of metastatic disease in melanoma patients, showing elevated plasma levels in metastatic disease and increased protein expression in melanocytic lesions. The combination of OPN with the well-established tumour marker S100 might increase the prediction of metastases.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ
Additional Notes Article first published online: 12 AUG 2011

Document type: Journal Article
Sub-type: Article (original research)
Collections: Official 2013 Collection
Institute for Molecular Bioscience - Publications
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 8 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 24 Jan 2012, 14:37:14 EST by Susan Allen on behalf of Institute for Molecular Bioscience